新辅助化疗联合全腔镜Mckeown术对中上段食管癌患者血清TGF⁃β1、鳞状细胞癌相关性抗原及远期疗效的影响  

Effect of neoadjuvant chemotherapy combined with total endoscopic Mckeown procedure on serum TGF⁃β1,squamous cell carcinoma⁃associated antigen and long⁃term curative effect in patients with middle and upper esophageal cancer

作　　者：周经月 解明华 张干 ZHOU Jingyue;XIE Minghua;ZHANG Gan(Department of Thoracic Surgery,the First Affiliated Hospital of University of Science and Technology of China(Anhui Provincial Hospital),Hefei 230001,China)

机构地区：[1]中国科技大学附属第一医院(安徽省立医院)胸外科,合肥230001

出　　处：《实用医学杂志》2021年第16期2109-2113,共5页The Journal of Practical Medicine

基　　金：2020年安徽省重点研究与开发计划项目(编号:202004j07020018)。

摘　　要：目的探究新辅助化疗联合全腔镜Mckeown术对中上段食管癌患者血清转化生长因子⁃β1(TGF⁃β1)、鳞状细胞癌相关性抗原(SCC)及远期疗效的影响。方法回顾性收集于我院接受诊疗的96例中下段食管癌患者临床资料,根据治疗方法不同分为两组。观察组采取新辅助化疗联合全腔镜Mckeown术治疗,对照组采取单纯全腔镜Mckeown术治疗。比较两组患者TGF⁃β1、SCC水平,统计和分析两组患者生存质量、复发情况、生存率以及远期并发症发生情况。结果术后3个月,两组患者血清TGF⁃β1、SCC水平均显著低于术前(P<0.05),且观察组患者血清TGF⁃β1、SCC水平显著低于对照组(P<0.05);术前,两组患者生存质量得分比较差异无统计学意义(P>0.05),但术后6、9个月,观察组患者生存质量得分均显著高于对照组(P<0.05);观察组患者随访期间复发率以及复发时间均显著低于对照组(P<0.05);术后1年,两组患者生存率比较差异无统计学意义(P>0.05);但术后3、5年,观察组患者生存率均显著高于对照组(P<0.05);观察组患者远期并发症发生率与对照组比较差异无统计学意义(P>0.05)。结论新辅助化疗联合全腔镜Mckeown术治疗能有效降低中上段食管癌患者血清TGF⁃β1、SCC水平,远期疗效相对可靠。Objective To investigate the effect of neoadjuvant chemotherapy combined with total endo⁃scopic Mckeown procedure on serum transforming growth factor⁃β1(TGF⁃β1),squamous cell carcinoma(SCC)⁃associated antigen and long⁃term curative effect in patients with middle and upper esophageal cancer.Methods The clinical data of 96 patients with middle and upper esophageal cancer in the hospital were retrospectively analyzed.According to the treatment method,they were divided into two groups.Patients in the study group were treated with neoadjuvant chemotherapy and subjected to total endoscopic Mckeown procedure,while patients in the control group were subjected to total endoscopic Mckeown procedure alone.The levels of TGF⁃β1 and SCC in the two groups were compared,and quality of life,recurrence,survival rate and the incidence of long⁃term complications in the two groups were analyzed.Results At 3 months after operation,serum TGF⁃β1 and SCC level in the two groups were significantly lower than those before operation(P<0.05,respectively),and serum TGF⁃β1 and SCC level in the study group were significantly lower than those in the control group(P<0.05,respectively).Before operation,no significant difference in quality of life scores was observed between the two groups(P>0.05),but patients in the study group had significantly higher quality of life scores than those in the control group at 6 and 9 months after operation(P<0.05).The recurrence rate and recurrence time in the study group during the follow⁃up period were significantly lower and shorter than those in the control group(P<0.05,respectively).One year after operation,there was no significant difference in the survival rate between the two groups(P>0.05),but the sur⁃vival rate in the study group was significantly higher than that in the control group at 3 and 5 years after operation(P<0.05).There was no significant difference in the incidence of long⁃term complications between the two groups(P>0.05).Conclusion Neoadjuvant chemotherapy combin

关 键 词：新辅助化疗 全腔镜Mckeown术 食管癌 TGF⁃β1 SCC 远期疗效 

分 类 号：R735.1[医药卫生—肿瘤]